Silvia S. Jurisson
Professor of Chemistry & Radiology
29 Schlundt Hall


BS, University of Delaware, 1978
PhD, University of Cincinnati, 1982

Professional Experience: 

Professional Service
Vice-Chair (2008), Chair-Elect (2009), Chair (2010) for the Division of Nuclear Chemistry and Technology, American Chemical Society
Member (2006-2012, 2014-2015), Board of Directors, Society of Radiopharmaceutical Science (elected)
Councilor (2014-2016) for the Division of Nuclear Chemistry and Technology, American Chemical Society
Associate Editor, Radiochimica Acta, 2013-present
Editorial Boards, Nuclear Medicine and Biology (1994-present) and the Journal of Radioanalytical and Nuclear Chemistry (2001-present)

Professional Experience
Professor, Missouri, 2001-present
Associate Professor, Missouri, 1997-2001
Assistant Professor, Missouri, 1991-1997
Research Investigator, MURR, 1995-present
Senior Research Investigator, Squibb and Bristol-Myers Squibb, 1989-1991
Research Investigator, the Squibb Institute for Medical Research, 1986-1989
Postdoctorate, University of Missouri-Columbia, 1984-1986
Postdoctorate, Australian National University, 1984
Postdoctorate, University of New South Wales, 1983-1984

Honors and Awards

2016 ACS Fellow (elected)

2015 Chair, International Symposium on Radiopharmaceutical Sciences (ISRS2015), MU Campus, Columbia, MO, 26-31 May 2015

2014 AAAS Fellow (elected)

2014 Fuldner Faculty Fellow in Chemistry, University of Missouri

2013 Fuldner Faculty Fellow in Chemistry, University of Missouri

2013 A&S Purple Chalk Teaching Award, University of Missouri

2012 Glenn T. Seaborg Award in Nuclear Chemistry, American Chemical Society (ACS)

2000 MU Faculty Development Leave Award

1996 MU Summer Research Fellowship

1996 MU Alumni Faculty Incentive Award

1995 MU Arts & Science Assistant Professor Travel Award

1993 MU Faculty Development Award

1992 MU Summer Research Fellowship


Research Emphasis: 

Inorganic and Radiopharmaceutical Chemistry including targetry, separations and radiotracer syntheses, Technetium Clathrochelates, Radiotracers in Plant Biology

My research interests involve several different, yet related, areas of radioinorganic chemistry. One area focuses on the utilization of gamma and beta emitting radiometals in the development of potential diagnostic and therapeutic radiopharmaceuticals. A second area addresses methods for the detection and separation of radiometals, in particular technetium-99, for minimization and safe storage of radioactive waste. A third area involves the use of radiotracers to understand plant and microbial biology. All research areas are multidisciplinary and therefore involve collaborations with other scientists within the department as well as in other departments, and at other institutions.

The area of radiopharmaceutical chemistry involves radioisotope production methods, development of separation methods, syntheses of ligands and coordination complexes, radiochemical syntheses, biochemistry, biology and radiology. We are focusing on the development of high specific activity radionuclides for these applications, in particular, Tc-99m, Re-188, Rh-105, Au-199, Pm-149, Ho-166, Lu-177, Ga-68, In-111, and As-72/77. We are using combinatorial chemistry approaches as well as traditional chemistry approaches to design better targeting molecules for receptors on tumors. We have been interested in the development of the chemistry, radiochemistry and biochemistry of potential diagnostic and therapeutic radiopharmaceuticals whose mode of targeting uses small biological molecules (e.g., peptides, antibody fragments, etc.). The primary targets to date have been melanoma, breast cancer, prostate cancer and neuroendocrine cancers. We have developed new ligand systems for rhodium(III), gold(III), and various oxidations states of rhenium and technetium. The ligand systems developed include thioether, phosphine, amine, imine, Schiff base, and thiolate functionalities for coordination to the various metals. Our emphasis is on developing metal complexes that are kinetically inert under physiological conditions. Our studies include the development of targets (accelerator and reactor), target-product separations (e.g., Re-186, As-72, As-77), the synthesis of new ligand systems (generally tetradentate), the synthesis of the transition metal complexes, the synthesis of the radiotracer analogs of these complexes, the determination of the stability of these complexes under physiological conditions, the determination of the binding of the various complexes to the appropriate receptors (in vitro), and the determination of the in vivo behavior of these complexes in both normal and tumor model mice. We are also interested in the similarities and differences in the chemistry of analogous Tc and Re compounds, such as the rates of formation and substitution, the mechanisms of formation, and their electrochemical behavior. These studies are important to the development of potential therapeutic radiopharmaceuticals based on Re.

The area of radioenvironmental chemistry involves radiochemistry, inorganic chemistry and analytical chemistry. Technetium-99 is a long-lived radionuclide produced in about 6% yield from the fission of U-235 and Pu-239 used as fuel in nuclear reactors and weapons. Thus, it is a large component of the waste generated from the nuclear weapons era and from nuclear fuel reprocessing. The combination of its long half-life (212,000 years) and its mobility in the environment as the oxoanion pertechnetate makes Tc-99 a problem for long term storage and environmental migration. We have investigated the use of supramolecular hosts and phosphinimines to selectively bind pertechnetate, and sulfide reduction in the presence of mineral phases to investigate the immobilization of Tc-99.

The area of radiotracers in plant biology involves the use of radiolabeled molecules (e.g., F-18-fluorosucrose, S-35-glutathione, Fe-59, Cd-111) to probe mechanistic processes in plants such as transport or signaling, and to investigate potential phytoremediation.

Select Publications

“Molecular Imaging Investigations of a 67Ga/64Cu labeled bivalent ligand, [RGD-Glu-(DO3A)-6-Ahx-RM2], targeting GRPR/αVβ3 Biomarkers: a Comparative Study”, Z. Jiang, R. P. Bandari, T. J. Stott Reynolds, J. Xu, Y. Miao, T. L. Rold, A. F. Szczodroski, S. S. Jurisson, C. J. Smith, Radiochim. Acta 2016, 104(7), 499-512.

“Dithiol Aryl Arsenic Compounds as Potential Diagnostic and Therapeutic Radiopharmaceuticals”, A. J. DeGraffenreid, Y. Feng, D. E. Wycoff, R. Morrow, M. D. Phipps, C. S. Cutler, A. R. Ketring, C. L. Barnes, S. S. Jurisson, Inorg. Chem. 2016,  55(16), 8091-8098.

“Accelerator-Based Production of the Diagnostic 99mTc/Therapeutic 186Re Pair using Metal Disulfide Targets (MoS2, WS2, OsS2)”, M. D. Gott, C. R. Hayes, D. E. Wycoff, E. R. Balkin, B. E. Smith, C. S. Cutler, A. R. Ketring, D. S. Wilbur, S. S. Jurisson, Appl. Radiat. Isot. 2016, 114, 159-166.

“Chromatographic Separation of Germanium and Arsenic for the Production of High Purity 77As”, M. D. Gott, A. J. DeGraffenreid, Y. Feng, M. D. Phipps, D. E. Wycoff, M. F. Embree, C. S. Cutler, A. R. Ketring, S. S. Jurisson, J.Chromatography A 2016, 1441, 68-74.

“Trithiols and their Arsenic Compounds for Use in Diagnostic and Therapeutic Applications”, A. J. DeGraffenreid, Y. Feng, C. S. Cutler, A. R. Ketring, C. L. Barnes, S. S. Jurisson, Nucl. Med. Biol. 2016, 43(5), 288-295.

“Synthesis, Characterization and In Vitro Evaluation of New 99mTc/Re(V)-cyclized Octreotide Analogues: An Experimental and Computational Approach”, Y. Li, L. Ma, V. Gaddam, F. Gallazzi, H. M. Hennkens, M. Harmata, M. R. Lewis, C. A. Deakyne, S. S. Jurisson, Inorg. Chem. 2016, 55, 1124-1133“Monooxorhenium(V) complexes with 222-N2S2 MAMA ligands for bifunctional chelator agents: Synthesis and preliminary in vivo evaluation”, D. W. Demoin, W. D. Minard, F. Gallazzi, G. L. Sieckman, T. L. Rold, N. Bernskoetter, T. J. Hoffman, C. A. Deakyne, S. S. Jurisson, Nucl. Med. Biol. 2016, 43(12), 802-811.

“Synthesis and evaluation of fac-[99mTc/Re(CO)3]+ complexes with a new (N,S,N) bifunctional chelating agent: The first example of a fac-[Re(CO)3(N,S,N-sst2-ANT)] complex bearing a somatostatin receptor antagonist peptide”, G. Makris, L. Radford, F. Gallazzi, S. Jurisson, H. Hennkens, D. Papagiannopoulou, J. Organomet. Chem. 2016 805, 100-107.

"Radiosynthesis of 6’-deoxy-6’[18F]fluorosucrose via automated synthesis and its utility to study in vivo sucrose transport in maize (Zea mays) leaves”, D. Rotsch, T. Brossard, S. Bihmidine, W. Ying, V. Gaddam, M. Harmata, J. D. Robertson, M. Swyers, S. Jurisson, D. M.  Braun, PLOS ONE 2015 10(5), e0128929/1-18.

“Chromatographic Separation of Selenium and Arsenic: A Potential 72Se/72As Generator”, D. E. Wycoff, M. D. Gott, A. J. DeGraffenreid, R. P. Morrow, N. Sisay, M. F. Embree, B. Ballard, M. E. Fassbender, C. S. Cutler, A. R. Ketring, S. S. Jurisson, J. Chromatography A 2014, 1340, 109-114.

““OPT3  is a Component of the Iron-Signaling Network between Leaves and Roots and Misregulation Leads to an over-accumulation of  cadmium in opt3-2 seeds”, D. Mendoza-Cozatl, Q. Xie, G. Akmakjian, Z. Garo, T. O. Jobe, A. Patel, M. G. Stacey, L. Song, D. Demoin, S. Jurisson, G. Stacey, J. Schroeder, Molecular Plant 2014, 7, 1455-1469.

“Novel rhenium(III, IV, and V) tetradentate N2O2 Schiff base mononuclear and dinuclear complexes”, D. A. Rotsch, K. M. Reinig, E. M. Weis, A. B. Taylor, C. L. Barnes, S. S. Jurisson, Dalton Trans. 2013, 42(32), 11614-11625.

“Inorganic chemisty in nuclear imaging and radiotherapy: current and future directions”, V. Carroll, D. W. Demoin, T. J. Hoffman, S. S. Jurisson (invited), Radiochim. Acta 2012, 100, 653-667.

“Method and basis set analysis of oxorhenium(V) complexes for theoretical calculations”, D. W. Demoin, Y. Li, S. S. Jurisson, C. A. Deakyne, Comput. Theor. Chem. 2012, 997, 34-41.